Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Proteome Sciences PLC - Drug development services provider - Secures a contract from major US academic group to evaluate changes on the proteome and phospho-proteome of tissue and blood samples taken from people with and without a neurodegenerative disease. The contract's value exceeds £500,000. Proteome refers to entire set of proteins in a cell or organism.
Chief Commercial Officer Richard Dennis said: ‘We are pleased that the SysQuant workflows that we offer has been selected by our client to quantitate the proteomic/phosphoproteomic changes in these research samples.’
Current stock price: 4.45 pence, up 8.5% on Thursday morning in London.
12-month change: down 48%
Copyright 2022 Alliance News Limited. All Rights Reserved